ARTICLE | Clinical News
Briviact regulatory update
February 3, 2017 12:40 AM UTC
FDA accepted for review an sNDA from UCB for Briviact brivaracetam as monotherapy to treat partial-onset seizures in epileptics ages ≥16. Last year, the agency approved the high affinity synaptic vesi...
BCIQ Company Profiles
BCIQ Target Profiles